A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or ...

or liposarcoma (LPS). The expansion cohort builds on the successful completion of monotherapy dose escalation and assignment of the SON-1010 maximum tolerated (MTD) dose of 1200 ng/kg ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft ...